Last update 23 Dec 2024

NX-5948

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras (PROTAC)
Synonyms
NX 5948, NX-5948
Target
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
RegulationFast Track (US), PRIME (EU)
Login to view timeline

Structure

Molecular FormulaC42H54N12O5
InChIKeyHPTPDBYCFHFWJG-CWTKIQHKSA-N
CAS Registry2649400-34-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaPhase 1
US
13 Apr 2022
Chronic Lymphocytic LeukemiaPhase 1
NL
13 Apr 2022
Chronic Lymphocytic LeukemiaPhase 1
GB
13 Apr 2022
Diffuse Large B-Cell LymphomaPhase 1
US
13 Apr 2022
Diffuse Large B-Cell LymphomaPhase 1
NL
13 Apr 2022
Diffuse Large B-Cell LymphomaPhase 1
GB
13 Apr 2022
Follicular LymphomaPhase 1
US
13 Apr 2022
Follicular LymphomaPhase 1
NL
13 Apr 2022
Follicular LymphomaPhase 1
GB
13 Apr 2022
Mantle-Cell LymphomaPhase 1
US
13 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
Chronic Lymphocytic Leukemia
Last line | Third line
34
ehxsmexaak(uiwuwmvklo) = Most common TEAEs were: purpura/contusion (44.1%, no Gr≥3); thrombocytopenia (23.5%, 2.9% Gr≥3); petechiae (29.4%, no Gr≥3); fatigue (20.6%, no Gr≥3); neutropenia (17.6%, 14.7% Gr≥3; pts with up to Gr 4 cytopenias were eligible for study participation); rash (23.5%, no Gr≥3, 2.9% SAE); headache (23.5%, no Gr≥3).There was no new onset atrial fibrillation/flutter or hypertension. bwvntmvxye (ptzbucbbls )
Positive
09 Dec 2024
Phase 1
79
iqkxvllsxm(nvempiowbm) = fukpohtkvx lciamdzmml (myzjthcaum )
Positive
19 Oct 2024
Phase 1
46
oeesynmyfz(pahnaftudt) = none pxrdofnegy (yjwaheacbe )
Positive
14 May 2024
Phase 1
7
jwforkgacg(xctcrpjsws) = havzbzzlkj fagggxkuna (lpwxisviun )
Positive
16 Jan 2024
Phase 1
B-Cell Lymphoma
Third line
14
dbpvvgvami(zypwfdfrai) = sswkkfwiwi armiqdzxcf (uukvkrqngy )
Positive
11 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free